Literature DB >> 17151056

Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier.

Balamurali K Ambati1, Emory Patterson, Pooja Jani, Crystal Jenkins, Eric Higgins, Nirbhai Singh, Tushar Suthar, Nehali Vira, Kimberly Smith, Ruth Caldwell.   

Abstract

PURPOSE: Pathological neovascularisation within the normally avascular cornea is a serious event that can interfere with normal vision. Upregulation of vascular endothelial growth factor (VEGF) has been associated with neovascularisation in the eye, suggesting that maintaining low levels of VEGF is important for corneal avascularity and intact vision. This study aims to determine the expression profile and possible contribution of sVEGFR-1 to the corneal avascular barrier.
DESIGN: Experimental case series investigating VEGF and soluble fms-like tyrosine kinase (sFlt) levels in normal and neovascularised human corneas. PARTICIPANTS: Four normal human corneas, five human corneas with alkali burns, three human corneas with aniridia, one with ocular cicatricial pemphigoid and two with interstitial keratitis were examined.
METHODS: Western blot and immunohistochemical analyses were performed to determine sFlt and VEGF levels in normal and neovascularised human corneas. Immunoprecipitation was utilised to demonstrate sFlt-VEGF binding.
RESULTS: Normal human corneas strongly express sFlt in the corneal epithelium and weakly in the corneal stroma close to the limbus. VEGF is bound by sFlt in the normal human cornea. Neovascularised human corneas have greatly reduced expression of sFlt and significantly less VEGF bound by sFlt.
CONCLUSIONS: sFlt is highly expressed in the human cornea and normally sequesters VEGF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151056      PMCID: PMC1994740          DOI: 10.1136/bjo.2006.107417

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Targeting multiple biological pathways as a strategy to improve the treatment of cancer.

Authors:  Michael S O'Reilly
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

2.  Inhibition of vascular endothelial growth factor activity by transfection with the soluble FLT-1 gene.

Authors:  H Chen; U Ikeda; M Shimpo; Y Maeda; M Shibuya; K Ozawa; K Shimada
Journal:  J Cardiovasc Pharmacol       Date:  2000-10       Impact factor: 3.105

3.  Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.

Authors:  C M Lai; M Brankov; T Zaknich; Y K Lai; W Y Shen; I J Constable; I Kovesdi; P E Rakoczy
Journal:  Hum Gene Ther       Date:  2001-07-01       Impact factor: 5.695

4.  Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor.

Authors:  H L Kong; D Hecht; W Song; I Kovesdi; N R Hackett; A Yayon; R G Crystal
Journal:  Hum Gene Ther       Date:  1998-04-10       Impact factor: 5.695

5.  Corneal avascularity is due to soluble VEGF receptor-1.

Authors:  Balamurali K Ambati; Miho Nozaki; Nirbhai Singh; Atsunobu Takeda; Pooja D Jani; Tushar Suthar; Romulo J C Albuquerque; Elizabeth Richter; Eiji Sakurai; Michael T Newcomb; Mark E Kleinman; Ruth B Caldwell; Qing Lin; Yuichiro Ogura; Angela Orecchia; Don A Samuelson; Dalen W Agnew; Judy St Leger; W Richard Green; Parameshwar J Mahasreshti; David T Curiel; Donna Kwan; Helene Marsh; Sakae Ikeda; Lucy J Leiper; J Martin Collinson; Sasha Bogdanovich; Tejvir S Khurana; Masabumi Shibuya; Megan E Baldwin; Napoleone Ferrara; Hans-Peter Gerber; Sandro De Falco; Jassir Witta; Judit Z Baffi; Brian J Raisler; Jayakrishna Ambati
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

6.  Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.

Authors:  Y He; S K Smith; K A Day; D E Clark; D R Licence; D S Charnock-Jones
Journal:  Mol Endocrinol       Date:  1999-04

7.  Rapid ocular angiogenic control via naked DNA delivery to cornea.

Authors:  S U Stechschulte; A M Joussen; H A von Recum; V Poulaki; Y Moromizato; J Yuan; R J D'Amato; C Kuo; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-08       Impact factor: 4.799

8.  Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1.

Authors:  J W B Bainbridge; A Mistry; M De Alwis; E Paleolog; A Baker; A J Thrasher; R R Ali
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

9.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

Authors:  R L Kendall; G Wang; K A Thomas
Journal:  Biochem Biophys Res Commun       Date:  1996-09-13       Impact factor: 3.575

10.  Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier.

Authors:  Peter Gehlbach; Anna Maria Demetriades; Satoru Yamamoto; Tye Deering; Wei Hong Xiao; Elia J Duh; Hoseong S Yang; Hong Lai; Imre Kovesdi; Miguel Carrion; Lisa Wei; Peter A Campochiaro
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

View more
  37 in total

Review 1.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  PlexinD1 is required for proper patterning of the periocular vascular network and for the establishment of corneal avascularity during avian ocular development.

Authors:  Sam C Kwiatkowski; Ana F Ojeda; Peter Y Lwigale
Journal:  Dev Biol       Date:  2016-01-16       Impact factor: 3.582

3.  Eyes wide s-flt: clearly, avascular fidelity is a vascular endothelial growth factor family affair.

Authors:  Royce Mohan
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

Review 4.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

5.  Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction.

Authors:  Walter Cromer; Merilyn H Jennings; Yoshinubo Odaka; J Michael Mathis; J Steven Alexander
Journal:  Microcirculation       Date:  2010-10       Impact factor: 2.628

Review 6.  Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease.

Authors:  Stefano Barabino; Yihe Chen; Sunil Chauhan; Reza Dana
Journal:  Prog Retin Eye Res       Date:  2012-03-08       Impact factor: 21.198

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

8.  Expression of pro- and anti-angiogenic factors during the formation of the periocular vasculature and development of the avian cornea.

Authors:  Sam Kwiatkowski; Ravi P Munjaal; Teresa Lee; Peter Y Lwigale
Journal:  Dev Dyn       Date:  2013-04-24       Impact factor: 3.780

9.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

10.  Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age.

Authors:  Alexandre Berthaut; Pezhman Mirshahi; Nadia Benabbou; Dalel Azzazene; Camille Bordu; Amu Therwath; Jean-marc Legeais; Massoud Mirshahi
Journal:  Mol Vis       Date:  2009-09-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.